ABSTRACT OBJECTIVES This study sough to test whether elevated lipoprotein(a) levels and corresponding LPA risk genotypes (low number of kringle IV type 2 repeats, rs3798220 and rs10455872, minor allele carriers) are associated with an increased risk of heart failure (HF).
Elevated lipoprotein(a) levels are considered a genetically determined causal risk factor for coronary heart disease (4) (5) (6) (7) (8) (9) , and as recently shown, for aortic valve stenosis (AVS) (10) (11) (12) . However, it is unknown whether elevated lipoprotein(a) levels also contribute to the incidence of HF. Clarification of this issue may advance our understanding of the underlying causes of HF and ultimately lead to improved preventive and treatment strategies.
Lipoprotein(a) is a unique lipoprotein consisting of a cholesterol-laden, low-density lipoprotein-like particle bound to a large plasminogen-resembling glycoprotein, apolipoprotein(a) (4) . Plasma levels of lipoprotein(a) are primarily genetically determined by polymorphisms in the LPA gene coding for apolipoprotein(a). The kringle IV type 2 (KIV- 2) repeat polymorphism is particularly important; it determines apolipoprotein(a) size that correlates inversely with plasma lipoprotein(a) levels (4) (5) (6) .
In addition, a number of single nucleotide polymorphisms (SNPs) partly tracking the KIV-2 polymorphism are also strongly associated with plasma lipoprotein(a) levels (5, 7, 8) .
In the present study, we combined 2 large, wellcharacterized, general population studies, the Copenhagen City Heart Study (CCHS) and the Copenhagen General Population Study (CGPS), to achieve maximum statistical power. First, we tested the hypothesis that lipoprotein(a) levels are prospectively associated with risk of HF. We included analyses on MI and AVS for comparison. Second, we tested for genetic evidence of causality by examining the association of LPA risk genotypes (low number of KIV-2 repeats, minor allele carriers of rs3798220 and rs10455872 SNPs), which are associated with elevated plasma lipoprotein(a) levels, with risk of HF. We applied a study design, often termed a Mendelian randomization study, in which participants are stratified according to genotype (8, (13) (14) (15) . This type of study can be considered a naturally occurring version of a randomized clinical trial, because genotypes are randomly distributed in homogenous populations, and are comparable to the random allocation of treatment in clinical trials, minimizing confounding in both cases (13) (14) (15) LABORATORY ANALYSES. Lipoprotein(a) total mass was measured in plasma using mainly fresh or shortly frozen samples and using 3 comparable (Online Figures 3 and 4) estimates of the sum of repeats on both alleles (6) . The LPA rs3798220 and rs10455872 SNPs were TaqMan genotyped in HardyWeinberg equilibrium. SNP carriers were minor allele homozygotes and heterozygotes combined: 0.02% and 2.48%, respectively, for rs3798220; and 0.64% and 13.61%, respectively, for rs10455872. We also calculated the population-attributable risk of HF for elevated lipoprotein(a) levels as: We conducted instrumental variable analysis, which is a formal test for causality, integrating the association of genotype with plasma lipoprotein(a) levels and the association of genotype with risk of HF. Analyses based on each of the 3 separate LPA genotypes was used to estimate causal relative risk estimates of HF for a 10-fold increase in lipoprotein(a) levels (6) . In addition, we estimated the causal relative risk based on all 3 genotypes combined using an individual participant data approach, thus including only participants with complete information on genotypes and lipoprotein(a) measurements (13) . For comparison with genetic estimates, we also estimated the observational multivariable adjusted odds ratio of HF for a 10-fold increase in plasma lipoprotein(a) levels.
Age-and sex-adjusted mediation analyses (16) were conducted to estimate the proportion of increased risk of HF due to elevated lipoprotein(a) plasma levels or LPA risk genotypes that was mediated through MI and/or AVS. Table 1 shows baseline characteristics of the 98,097
RESULTS

CCHS and CGPS participants [all and by lipoprotein(a)
percentiles], of whom 4,122 had a diagnosis of HF.
Online Table 1 lists the baseline characteristics stratified on LPA KIV-2 percentile groups. Online Figure 1 shows the number of participants included in main analyses; a total of 98,097 participants were included in at least 1, and the large majority (>79,000) in at least 2, main analyses. (20) (21) (22) (23) (24) (25) (26) (27) (28) similar in age-and sex-adjusted and in multivariableadjusted analyses (Figure 2A ). The populationattributable risk of HF was 9% for elevated lipoprotein(a) levels.
In accordance with previous results (6,11), we similarly observed stepwise increases in risk of incident MI and AVS with increasing lipoprotein(a) levels (Online Figure 5) . Accordingly, risk estimates for HF were attenuated when excluding participants diagnosed with MI or AVS at any time before (or at the time of) a diagnosis of HF ( Figure 2B) Figure 6 ).
LPA GENOTYPES AND RISK OF HEART FAILURE. In accordance with previous results (6,11), a low number of LPA KIV-2 repeats and minor allele carrier status for LPA rs3798220 or rs10455872 were associated with elevated lipoprotein(a) levels (tabular data in Figure 3 , all p < 0.001). Using analysis of variance, the LPA KIV-2 genotype explained 29%, the rs3798220 genotype 6%, the rs10455872 genotype 31%, and all 3 genotypes combined explained 46%, of the total variation in plasma lipoprotein(a) levels.
We observed increased risk of HF for all risk ge- Figure 4) . When we excluded individuals with previous MI or AVS, genetic odds ratios were generally attenuated, but remained significant for KIV-2 and rs3798220 genotypes, as was the observational estimate ( Figure 4) .
MEDIATION ANALYSES. Forty-seven percent (95% CI: 32% to 77%) of increased HF risk due to elevated lipoprotein(a) levels was mediated through MI, and likewise 21% (14% to 34%) through AVS ( Table 2) .
Considered together, 63% (45% to 99%) of the increased HF risk due to elevated lipoprotein(a) levels was mediated through MI and/or AVS (some participants were diagnosed with both MI and AVS). Findings were similar for increased risk of HF due to LPA risk genotypes, albeit with wide CIs for rs10455872
( Table 2) .
DISCUSSION
In the present general population study, we demonstrated a stepwise increase in risk of HF with increasing levels of lipoprotein(a), and risk was increased 1.6-to 1.8-fold for levels >90th percentile.
Furthermore, we demonstrated a clear association of 3 LPA risk genotypes [determining elevated Results from the present study are consistent with elevated lipoprotein(a) levels promoting HF at least partly via an increased risk of coronary heart disease and aortic valve disease, where lipoprotein(a) levels >90th percentile predict a 2-to 3-fold increased risk of these diseases (6, 11) . Risk estimates for HF were attenuated, but were generally still statistically sig- Importantly, the uniformity of study participants excluded population admixture, which might lead 
